Objective: The paper investigated the disease burden and economic burden of patients with multiple sclerosis (MS) to provide empirical data for further improving the management of MS patients in China. Methods: Cross-sectional survey was conduted in hospitals to analyze patients' diagnosis and treatment, disease burden and economic burden. Generalized linear models (GLMs) were used to model the association between the current EDSS score and costs. Results: Delayed medical diagnosis and treatment were common among patients with MS. 82% of the patients are of working age, among which 25% are in long-term sick leave, unemployment or retirement, with a serious disease burden. At the same time, disease progression also has serious negative impact on patients' daily activities, psychological and cognitive functions. As the EDSS score increases, the economic burden increases significantly. Conclusion: Early diagnosis and treatment of the MS should be emphasized to alleviate the severe burden to the patients' family and the whole society.
Key words
multiple sclerosis /
burden of disease /
economic burden of disease /
societal perspective /
China
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
[1] 邱伟,徐雁.多发性硬化诊断和治疗中国专家共识(2018版)[J].中国神经免疫学和神经病学杂志, 2018, 25(06): 387-394.
[2] OH J, VIDAL-JORDANA A, MONTALBAN X.Multiple sclerosis: clinical aspects[J/OL]. Current Opinion in Neurology, 2018, 31(6): 752-759. DOI:10/ghtdc2.
[3] WALLIN M T, CULPEPPER W J, NICHOLS E.Global, regional, and national burden of multiple sclerosis 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016[J/OL]. The Lancet Neurology, 2019, 18(3): 269-285. DOI:10/gfzcrh.
[4] 国家卫生健康委员会.罕见病诊疗指南(2019版)[R/OL]. (2019). http://www.nhc.gov.cn/yzygj/s7659/201902/61d06b4916c348e0810ce1fceb844333/files/e2113203d0bf45d181168d855426ca7c.pdf.
[5] XU L, CHEN L, WANG S.Urban prevalence of multiple sclerosis in China: A population-based study in six provinces[J/OL]. European Journal of Neurology, 2021, 28(5): 1636-1644. DOI:10/gmntwg.
[6] TIAN D C, ZHANG C, YUAN M, 等. Incidence of multiple sclerosis in China: A nationwide hospital-based study[J/OL]. The Lancet Regional Health. Western Pacific, 2020, 1: 100010. DOI:10/gg8r4p.
[7] ÇINAR B P, YORGUN Y G.What We Learned from The History of Multiple Sclerosis Measurement: Expanded Disability Status Scale[J/OL]. Archives of Neuropsychiatry, 2018, 55(Suppl 1): S69-S75. DOI:10/gmntwf.
[8] ANDERSON P, BENFORD M, HARRIS N.Real-world physician and patient behaviour across countries: Disease-Specific Programmes - a means to understand[J/OL]. Current Medical Research and Opinion, 2008, 24(11): 3063-3072. DOI:10.1185/03007990802457040.
[9] BARBER J, THOMPSON S.Multiple regression of cost data: use of generalised linear models[J/OL]. Journal of Health Services Research & Policy, 2004, 9(4): 197-204. DOI:10.1258/1355819042250249.
[10] FREEMAN L, KEE A, TIAN M.Retrospective Claims Analysis of Treatment Patterns, Relapse, Utilization, and Cost Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy[J/OL]. Drugs - Real World Outcomes, 2021, 8(4): 497-508. DOI:10.1007/s40801-021-00251-w.
[11] CAMPBELL J A, SIMPSON S, AHMAD H.Change in multiple sclerosis prevalence over time in Australia 2010-2017 utilising disease-modifying therapy prescription data[J/OL]. Multiple Sclerosis Journal, 2020, 26(11): 1315-1328. DOI:10.1177/1352458519861270.
[12] 人民网.我国首部《多发性硬化患者生存报告(2018)》发布[EB/OL]. (2019-02-25)[2022-05-26]. http://health.people.com.cn/n1/2019/0225/c14739-30901332.html.
[13] GUOJUN T, YAN X, WEIZHI W.A multicenter study to evaluate the disease burden and health economics of inpatients with multiple sclerosis in China[J/OL]. Multiple Sclerosis and Related Disorders, 2022, 60: 103732. DOI:10.1016/j.msard.2022.103732.
[14] DU Y, MIN R, ZHANG X.Factors associated with the healthcare expenditures of patients with multiple sclerosis in urban areas of China estimated by a generalized estimating equation[J/OL]. Expert Review of Pharmacoeconomics & Outcomes Research, 2021, 21(1): 137-144. DOI:10/gmntwd.
